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Lung cancer is the leading cause of cancer   
deaths in both men and women in the 
United States (American Cancer Society 
2008). Worldwide, it has been estimated that 
20–30% of males and 5–20% of females of 
working age have been occupationally exposed 
to agents that cause lung cancer (World Health 
Organization 2002). Chronic inflammation 
has been implicated in the development of 
a wide array of human cancers, including 
lung cancer (reviewed by Coussens and Werb 
2002). Inflammatory cells and their chemical 
mediators are key participants in the generation 
of a tumor micro  environment that promotes 
angiogenesis and participates in cancer metas-
tases (Albini and Sporn 2007). Individuals 
with under  lying inflammation in the lung 
due to chronic infection, asbestos exposure, 
or development of interstitial lung disease and 
asthma are at an increased risk for lung can-
cer (Santillan et al. 2003; Turner et al. 2007; 
Yang et al. 2005). Furthermore, a decreased 
risk of lung cancer has been reported with the 
use of nonsteroidal anti  inflammatory drugs, 
further suggesting a role of inflammation in 
lung cancer pathogenesis (Khuder et al. 2005; 
Van Dyke et al. 2008).
Certain hexavalent chromium [Cr(VI)] 
compounds are occupational and potential 
environmental human respiratory carcino-
gens [International Agency for Research on 
Cancer (IARC) 1990]. Workers in the chro-
mate production industry have an elevated 
risk of respiratory diseases, including fibro-
sis, hyperplasia of the bronchial epithelium, 
lung fibro  sarcomas, adeno  carcinomas, and 
squamous cell carcinomas (reviewed by IARC 
1990). Outside of commercial use, Cr(VI) is 
a component of industrial waste, and atmo-
spheric particulate Cr is generated by combus-
tion of fossil fuels, wearing of brake linings, 
ferrochrome and cement production, ore 
refining, refractory processing, welding, and 
incineration of all types [Agency for Toxic 
Substances and Disease Registry (ATSDR) 
2000; Fishbein 1981]. Upon inhalation, 
Cr particles accumulate at the bifurcations 
of the bronchi, and the concentration of Cr 
in these regions of the lung can reach up to 
15.8 mg/g of tissue (Ishikawa et al. 1994). 
Animal studies illustrate that slightly soluble 
and highly insoluble Cr(VI) particulates such 
as chromates of zinc, lead, strontium, barium, 
and sintered calcium consistently induced a 
tumor response, albeit with variable efficacy 
(reviewed by IARC 1990). 
Aberrant cell survival, proliferation, and 
tissue remodeling contribute to the etiology of 
lung cancer (Hanahan and Weinberg 2000). 
An important survival signaling protein in 
the lung is the kinase Akt, which is activated 
by phosphorylation at Ser-473 and Thr-308 
(reviewed by Bellacosa et al. 1991). Akt acti-
vation initiates a cascade of signaling events 
that affect neo  vascularization, proliferation, 
and inhibition of apoptosis (Altomare and 
Testa 2005). Increased levels of phosphory-
lated Akt (  phospho-Akt) have been associated 
with non-small-cell lung cancer, and increased 
phospho-Akt staining intensity correlates with 
poor patient prognosis (Altomare and Testa 
2005). We have previously shown that a single 
exposure of particulate Cr(VI) induces toxic 
mucosal injury and an acute inflammatory 
response characterized by the up-regulation 
of interleukin-6 (IL-6) and growth-regulated 
oncogene-α (Gro-α), phosphorylation of Akt, 
and infiltration of neutrophils and lympho-
cytes into the lung (Beaver et al. 2009). Tissue 
remodeling is critically dependent on matrix 
metalloproteases (MMPs), which are frequently 
activated during lung injury, inflammation, 
and cancer development. Activation of MMPs 
results in the degradation of collagens in the 
extracellular matrix (reviewed by Coussens and 
Werb 2002).
We hypothesize that particulate Cr(VI) 
will induce an inflammatory microenviron-
ment in the lung that will promote prolif-
eration and selection of growth-altered cells. 
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Ba c k g r o u n d: Chronic inflammation is implicated in the development of several human cancers, 
including lung cancer. Certain particulate hexavalent chromium [Cr(VI)] compounds are well- 
documented human respiratory carcinogens that release genotoxic soluble chromate and are asso-
ciated with fibrosis, fibrosarcomas, adenocarcinomas, and squamous cell carcinomas of the lung. 
Despite this, little is known about the pathologic injury and immune responses after repetitive 
exposure to particulate chromates.
oBjectives: In this study we investigated the lung injury, inflammation, proliferation, and survival 
signaling responses after repetitive exposure to particulate chromate. 
Me t h o d s : BALB/c mice were repetitively treated with particulate basic zinc chromate or saline 
using an intranasal exposure regimen. We assessed lungs for Cr(VI)-induced changes by broncho-
alveolar lavage, histologic examination, and immunohistochemistry.
re s u l t s: Single exposure to Cr(VI) resulted in inflammation of lung tissue that persists for up to 
21 days. Repetitive Cr(VI) exposure induced a neutrophilic inflammatory airway response 24 hr 
after each treatment. Neutrophils were subsequently replaced by increasing numbers of macrophages 
by 5 days after treatment. Repetitive Cr(VI) exposure induced chronic peribronchial inflammation 
with alveolar and interstitial pneumonitis dominated by lymphocytes and macrophages. Moreover, 
chronic toxic mucosal injury was observed and accompanied by increased airway pro-matrix metal-
loprotease-9. Injury and inflammation correlated with airways becoming immuno  reactive for phos-
phorylation of the survival signaling protein Akt and the proliferation marker Ki-67. We observed a 
reactive proliferative response in epithelial cells lining airways of chromate-exposed animals.
co n c l u s i o n s: These data illustrate that repetitive exposure to particulate chromate induces chronic 
injury and an inflammatory microenvironment that may promote Cr(VI) carcinogenesis.
key w o r d s : chromium, hexavalent, inflammation, injury, intranasal, lung, proliferation, repair. 
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We investigated the inflammatory processes, 
tissue injury, and changes in markers associ-
ated with dysregulated cell proliferation after 
repetitive exposure to particulate Cr(VI). We 
used particulate basic zinc chromate because 
it is a moderately insoluble form of Cr(VI) 
that yields a fairly consistent tumor response in 
mice (Steffee and Baettjer 1965). Furthermore, 
studies on zinc compounds in cell culture or 
inhalation exposure demonstrate that zinc has 
little toxicologic or immunologic consequence 
in the lung (Wallenborn et al. 2008). Our find-
ings demonstrate that repetitive exposure to 
Cr(VI) particles induces chronic tissue injury 
and inflammation that could provide the nec-
essary microenvironment for the development 
of Cr(VI)-mediated carcinogenesis.
Materials and Methods
Chromium preparation and intranasal admin-
istration. Female BALB/cJ mice were obtained 
from the National Cancer Institute (Frederick, 
MD) and were 6–8 weeks of age at first Cr(VI) 
treatment. All experiments were performed in 
accordance with and under the approval of the 
George Washington University Institutional 
Animal Care and Use Committee, and all ani-
mals were treated humanely and with regard 
for alleviation of suffering. We used fluorescent 
polystyrene particles (4 µm; Phosphorex, Inc., 
Fall River, MA) as a control to visualize deposi-
tion of particles (Figure 1F). Endotoxin-free 
basic zinc chromate [ZnCrO4 4Zn(OH)2] was 
4.7 µm in size and had a purity of 99–100% 
(Rockwood Pigments, Beltsville, MD) (Beaver 
et al. 2009). Cr(VI) was suspended in sterile 
0.9% sodium chloride solution at a concentra-
tion of 0.6 mg/mL and prepared as previously 
described (Beaver et al. 2009). Animals under 
a light anesthesia (isoflurane) were intra  nasally 
exposed to a 50-µL dose of chromate or saline 
and sacrificed by exposure to carbon dioxide at 
indicated time points. To determine the dura-
tion of injury and inflammation after Cr(VI) 
exposure, we conducted a set of experiments 
up to 21 days after a single Cr(VI) treatment. 
Repetitive Cr(VI) studies were conducted after 
the described exposure regimen (Figure 2A) for 
up to 69 days after the initial Cr(VI) exposure. 
Lungs of animals from both the single and 
repetitive exposure experiments were further 
analyzed for inflammation and injury. 
Flow cytometry and cytokine analysis. 
Mice were euthanized, airway cells were col-
lected from lungs at indicated time points by 
bronchoalveolar lavage (BAL), and the remain-
ing live cells were quantified and stained for 
fluorescence-activated cell sorting (FACS) 
analysis to detect neutrophils (Gr1), eosino-
phils (FcεRIα), T lymphocytes (CD3, CD4, 
and CD8), B cells (B220), alveolar mac-
rophages (CD11c), and tissue macrophages 
(CD11b), as previously described (Beaver et al. 
2009). Enzyme-linked immunosorbant assays 
(ELISAs) were performed on the supernatant 
of BAL fluid following manufacturer’s instruc-
tions to assess the presence of pro-MMP9 and 
the cytokines IL-6 and tumor necrosis factor-α 
(TNF-α) (ELISA kits from R&D Systems, 
Minneapolis, MN).
Histology. After BAL, whole lungs from 
each mouse were perfused with 20 mL chilled 
saline to remove red blood cells. Lungs were 
then fully expanded with 1 mL periodate-
lysine-paraformaldehyde fixative (0.01 M 
sodium m-periodate, 0.075 M lysine, 1% para-
formaldehyde) introduced through the trachea, 
which was tied closed with suture string to 
maintain the fully expanded state. To obtain 
complete fixation, tissues were submerged in 
fixative overnight and transferred into 70% eth-
anol. Fixed lung tissue was paraffin embedded, 
sectioned (4 µm), and stained by hematoxylin 
and eosin (H&E) (HistoServ, Germantown, 
MD) and Giemsa (Sigma-Aldrich, St. Louis, 
MO), as previously described (Beaver et al. 
Figure 1. Resolution of inflammation in BAL fluid (A–C) and lung sections (D–E) at indicated times after a 
single exposure to particulate Cr(VI) (50 µL of 0.6 mg/mL basic zinc chromate). (A) Total number of living 
cells. (B and C) Total number of neutrophils (Gr1+; B) and macrophages (CD11c+; C) determined by FACS 
analysis. (D and E) Representative bright-field photomicrographs of H&E-stained lung sections (original 
magnification, 20×) showing (D) airways and (E) alveolar regions. Arrows indicate regions of peribronchial 
inflammation. (F) Merged fluorescence (460–500 nm) and bright-field microscopy images of Giemsa-
stained lung tissue. Bars = 200 µm.
*p < 0.05 compared with control. 
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2009). Immunohistochemistry with phos-
pho-specific serine-473 Akt antibody (Cell 
Signaling, Danvers, MA) and Ki-67 antibody 
(MIB-1 clone; Dako, Carpinteria, CA) was 
also performed (HistoServ) (Tsurutani et al. 
2006). Bright-field photomicrographs were 
obtained using an Olympus DP70 micro-
scope digital camera (Olympus, Center Valley, 
PA) with supporting DPController and 
DPManager software on an Olympus Provis 
AX70 microscope with the indicated objective 
magnification.
Statistical analysis. To determine sig-
nificant differences among experimental 
groups, we performed statistical analyses with 
GraphPad Prism (GraphPad Software Inc., 
La Jolla, CA). We used two-tailed, unpaired 
t-tests when comparing two experimental 
groups. One-way analysis of variance and a 
Tukey or Dunnett’s post  test was performed 
for multiple sample comparisons. Results are 
presented as the mean ± SE, and p < 0.05 is 
considered significant. 
Results
Persistence of inflammation after Cr(VI) expo-
sure. In the present study, we first determined 
the kinetics of resolution of inflammation after 
a single Cr(VI) exposure to establish an optimal 
time course for sub  sequent exposures. Mice 
were intra  nasally exposed to basic zinc chro-
mate, and the number of cells in BAL fluid was 
evaluated as an initial measure of lung inflam-
mation. We observed a significant increase 
in the total number of viable cells—approxi-
mately 2.5 times the number of cells—in BAL 
fluid 1 and 8 days after chromate exposure 
compared with day 0 (Figure 1A). Cell num-
bers in BAL fluid returned to control levels by 
15 days after particulate Cr(VI) treatment and 
further declined by 21 days after treatment. 
A significant recruitment of neutrophils into 
BAL fluid was apparent 1 day after Cr(VI) 
exposure (Figure 1B), consistent with our pre-
vious observations (Beaver et al. 2009). This 
increase in neutrophils resolved within 7 days 
and was followed by an influx of macrophages 
into the BAL fluid that was apparent 8 days 
after Cr(VI) exposure (Figure 1C). The number 
of macrophages then returned to a basal level 
15 days after treatment and was significantly 
less than control samples 21 days after Cr(VI) 
exposure. We observed no T lymphocytes or 
eosinophils at any time (data not shown).
The persistence of inflammation was also 
examined in lung tissue. We observed peri-
bronchiolar inflammation 1 day after Cr(VI) 
exposure, which increased up to 8 days 
after intra  nasal treatment (Figure 1D). Peri-
bronchiolar inflammation began to resolve 
15 days after Cr(VI) exposure and was no lon-
ger apparent 21 days after treatment. Alveolar 
and interstitial inflammation was detected, 
consistent with a Cr(VI)-induced pneumonitis 
Figure 2. Effects of repetitive Cr(VI) exposure on airway inflammation. (A) Regimen of repetitive intranasal 
exposure of mice to 50 µL saline or 0.6 mg/mL basic zinc chromate suspended in saline. Number of neutro-
phils (Gr1+; B) and macrophages (CD11c+; C) in BAL fluid quantified by FACS analysis for 5–11 chromate-
treated animals and 6–7 saline-treated animals, expressed as fold of saline control. (D–I) Bright-field 
photomicrographs of H&E-stained lung sections obtained from mice 8 days after a single Cr(VI) exposure 
(D,F,H) or 6 days after the fourth exposure (E,G,I). Boxed areas in D and E (10×) are shown at a higher power 
in F and G (40×), respectively. (H) Lymphocytes and (I) macrophages in the lung (100×). Macrophages are 
indicated by asterisks; the arrow points to a binucleated or dividing macrophage. Bars = 200 µm in D and E; 
100 µm in F and G; and 30 µm in H and I. 
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(Figure 1E). The alveolar inflammation was 
most prominent 8 days after Cr(VI) treatment 
but remained detectable up to 21 days after 
exposure. Both peri  bronchiolar and alveolar 
inflammation were centrally located, whereas 
near-pleural regions remained uninvolved. 
Indeed, intra  nasal delivery of fluorescent beads, 
similar in size to zinc chromate, resulted in 
deposition that was primarily localized in foci 
in and around the respiratory and terminal 
bronchioles and the proximal alveolar ducts 
(Figure 1F). Furthermore, most of the particles 
were centrally located in the lung. Overall, these 
data illustrate that a single intra  nasal exposure 
to particulate Cr(VI) induces a significant 
inflammatory response in the lung that begins 
to resolve 15 days after Cr(VI) treatment, 
although inflammatory cells are still detectable 
up to 3 weeks after exposure.
Cr(VI)-induced chronic inflammation. 
Workers in the chromate industry are repeti-
tively exposed to particulate chromates (IARC 
1990). To examine the inflammatory response 
in the lung after repetitive particulate Cr(VI) 
exposure, we developed an intra  nasal regimen 
of basic zinc chromate or saline treatment 
(Figure 2A). This dosing regimen was chosen 
because inflammation began to resolve 2 weeks 
after a single Cr(VI) exposure (Figure 1). We 
evaluated the total number of cells in BAL 
fluid, which was consistently elevated at all 
time points examined (data not shown). A sig-
nificant recruitment of neutrophils into lung 
airways was apparent at all time points that 
were 24 hr after Cr(VI) exposure (Figure 2B). 






































Figure 3. Repetitive Cr(VI) exposure induced airway injury (A,B), Akt signaling (D–F), and epithelial pro-
liferation (G–J). Representative bright-field photomicrographs of H&E-stained (A,B) or immuno  histo-
chemically stained (D–J) lung sections obtained from mice at 24 hr after the fifth exposure to Cr(VI) (E–F 
and H–J) or saline (A,D,G). In (B) regions of airway with injured epithelium are indicated by asterisks.   
(C) pro-MMP9 levels measured in BAL fluid by ELISA in 5–8 mice. (D–F) Tissue sections labeled by 
phospho-specific serine-473 Akt antibody. (G–J) Tissue sections labeled by Ki-67 antibody; arrows 
indicate cells or regions of cells that are positive for Ki-67. Original magnification, 40×; bars = 100 µm.
#p < 0.0001 compared with the same-day saline control, as determined by t-test. Beaver et al.
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neutrophils compared with saline controls 
after the first and second Cr(VI) exposures, 
even greater increases (25-fold) were detected 
after the third and fourth Cr(VI) exposures. 
In contrast, no significant increase in neu-
trophil numbers was detected in the airways 
of mice sacrificed at time points between 
Cr(VI) exposures (Figure 2B). Macrophage 
numbers were significantly elevated (2-fold 
increase) in the airways between Cr(VI) chal-
lenges (Figure 2C). A small number of CD4+ 
or CD8+ T lymphocytes were occasionally 
detected in the airways, but these accounted 
for < 4% of the total immune cells in Cr(VI)-
exposed mice (data not shown). No eosino-
phils (FcεRIα positive) were observed either 
in the BAL fluid or in the peripheral blood 
of Cr(VI)-exposed animals (data not shown). 
Taken together, these data provide evidence of 
persistent inflammation of airways after repeti-
tive particulate Cr(VI) exposure.
To further understand the extent of 
inflammation induced by repetitive particu-
late Cr(VI) exposure, we examined gross 
changes in injury to airways and infiltration 
of immune cells. Peribronchiolar, alveolar, and 
interstitial inflammation was apparent in all 
Cr(VI)-exposed mice, at all time points ana-
lyzed (Figure 2D–G). Peribronchiolar inflam-
mation was predominantly localized around 
airways 200–400 µm in size. Although marked 
leuko  cytic infiltrates were detectable 8 days 
after the first Cr(VI) exposure, the extent 
of inflammation was further increased after 
multiple Cr(VI) treatments (Figure 2D–G). 
The inflammation remained centrally located 
in the lung, whereas near-pleural regions 
remained unaffected. The most abundant leu-
kocyte subset detected in Cr(VI)-exposed lung 
tissue at all time points examined was lym-
phoid cells (Figure 2H).
Histologic examination also revealed 
macrophages in the lung tissue of chromate-
exposed animals (Figure 2I). Interestingly, 
after repetitive Cr(VI) exposure, we occasion-
ally observed macrophages that were either 
binucleated or at the anaphase stage of mito-
sis (Figure 2I). Overall, the inflammation 
detected in Cr(VI)-exposed mice indicates 
chemical-induced pneumonitis. The histologic 
observations of inflammation were confirmed 
by FACS analysis of cell suspensions generated 
from lung tissue. We observed a significant 
3.1-fold increase in the number of immune 
cells present in lung tissue 24 hr after the fifth 
Cr(VI) exposure, which consisted of lymphoid 
cells (92.9% of total leukocytes), macrophages 
(4.6%), and neutrophils (2.6%). Most lym-
phoid cells were B cells (B220+), followed by 
a significant number of helper T cells (CD4+) 
and few cytotoxic T cells (CD8+) (data not 
shown). Overall, the pathology illustrates 
that repetitive intra  nasal exposure to particu-
late Cr(VI) induces a chronic inflammatory 
response in the lung.
Cr(VI)-induced lung injury. We examined 
lung tissue of mice to determine the type and 
extent of lung injury after repetitive particulate 
Cr(VI) exposure. Proximal and mid  proximal 
toxic bronchiolar mucosal injury was present 
in airways after repetitive Cr(VI) treatment 
(Figure 3B). This injury was characterized by 
degenerative changes and sloughing of epithe-
lial cells. The injury was centrally located in the 
lung, whereas nearby pleural regions remained 
uninvolved (data not shown). To further char-
acterize the Cr(VI)-induced injury, we meas-
ured the levels of pro-MMP9 in BAL fluid. 
Increases of 4.9- and 7.7-fold were detected in 
the pro-MMP9 level at 44- and 64-day time 
points, respectively (Figure 3C). These time 
points were 24 hr after a Cr(VI) challenge 
and correlated with the presence of neutro-
phils in the airways. We observed no differ-
ence in pro-MMP9 in the samples collected 
between Cr(VI) treatment at days 49 and 69 
(Figure 3C). No TNF-α or IL-6 was detected 
in the BAL fluid 24 hr after the fifth Cr(VI) 
exposure (data not shown).
Cr(VI)-induced Akt signaling and epithe-
lial proliferation. Mice intranasally exposed 
to particulate Cr(VI) up-regulated Akt phos-
phorylation at 1 and 24 hr after treatment 
(Beaver et al. 2009). We hypothesized that 
repetitive particulate Cr(VI) exposure could 
also induce a survival signaling mechanism 
in airway epithelial cells following Cr(VI) 
injury. Therefore, we meas  ured phosphoryla-
tion of Akt on Ser-473 at 24 hr after the fifth 
Cr(VI) or saline exposure. A basal level of 
phospho-Akt was detected in animals exposed 
to saline alone (Figure 3D). Repetitive Cr(VI) 
treatment resulted in increased intensity 
of phospho-Akt staining in epithelial cells 
lining airways injured by Cr(VI) exposure 
(Figure 3E). Additionally, phospho-Akt was 
detected in some inflammatory cells that 
were present in the Cr(VI)-treated lungs 
(Figure 3E). Interestingly, phospho-Akt was 
also detected in epithelial cells lining airways 
that displayed aberrant growth (Figure 3F).
Given the repetitive injury and pres-
ence of survival signaling in cells of particu-
late Cr(VI)-exposed airways, we postulated 
that cell proliferation would be induced. 
Ki-67 is extensively used as a proliferation 
marker, and a few Ki-67–positive cells were 
detected in airways of mice exposed to saline 
alone, representing a basal level of prolifera-
tion (Figure 3G). We observed an increase 
in Ki-67–positive cells in both injured 
(Figure 3I) and intact (Figure 3J) airways in 
response to repetitive particulate Cr(VI) expo-
sure. Interestingly, Ki-67–positive lymphoid 
cells were also detected in the lungs of mice 
repetitively exposed to particulate Cr(VI) 
(Figure 3H).
Lungs of Cr(VI)-exposed mice and saline 
controls were examined for any early signs 
of uncontrolled cell growth. We detected a 
proliferative response in epithelial cells lining 
the airways of mice repetitively exposed to 
Figure 4. Proliferative response in epithelial cells repetitively exposed to particulate Cr(VI) shown by rep-
resentative bright-field photomicrographs of H&E-stained lung sections obtained from mice 24 hr after the 
fifth saline or Cr(VI) exposure. (A,B) Original magnification of 10×; bars = 200 µm. (C,D) Boxed areas in A 
and B, respectively. Original magnification of 40×; bars = 100 µm. 
Saline Cr(VI)Cr(VI)-induced lung inflammation and proliferation
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particulate Cr(VI) (Figure 4). In these airways, 
the epithelial cells no longer formed a mono-
layer lining the airway, but rather demon-
strated cellular stratification. This proliferative 
response was detected in most Cr(VI)-exposed 
animals, whereas it was infrequently observed 
in mice exposed to saline alone.
Discussion
Chronic inflammation is involved in the 
pathogenesis of many cancers, including those 
of the lung (reviewed by Coussens and Werb 
2002; Lin and Karin 2007). In the present 
study, repetitive particulate Cr(VI) expo-
sure induced lung injury as well as a chronic 
inflammatory response that can be described 
as repeating waves of infiltrating leukocytes. 
At 24 hr after each Cr(VI) treatment, the pre-
dominant immune cells in the lung airways 
and tissue were neutro  phils and lymphoid 
cells, respectively. Five days after Cr(VI) expo-
sure, macrophages and lymphoid cells were the 
dominant infiltrating leukocytes. The inflam-
mation was predominately centrally located in 
the lung, which was consistent with the local-
ization of similarly sized fluorescent beads in 
small airways. This type of localization fits well 
with reports that the highest concentrations 
of Cr were detected at the bifurcations of the 
bronchi among chromate workers (Ishikawa 
et al. 1994).
The presence of neutrophils and macro-
phages in airways after repetitive Cr(VI) expo-
sure is consistent with welding fume studies 
in which a significant increase in neutrophils 
and macrophages was also detected in the 
lung of exposed rodents (Antonini et al. 2007; 
Solano-Lopez et al. 2006; Taylor et al. 2003; 
Zeidler-Erdely et al. 2008). Timing and dura-
tion of neutrophil and macrophage infiltra-
tions varied between the present Cr(VI) study 
and the welding fume studies, potentially due 
to the additional presence of iron, manganese, 
and nickel in welding fumes (Antonini et al. 
2007; Solano-Lopez et al. 2006; Taylor et al. 
2003). Observed increases in neutrophils and 
no change in macrophages 24 hr after zinc 
chromate exposure are also consistent with 
findings in rats exposed to potassium chromate 
and barium chromate (Cohen et al. 1998). 
The observed increase in macrophages several 
days after Cr(VI) exposure is consistent with 
chronic inhalation of low-dose soluble Cr(VI) 
observed in rats (Glaser et al. 1985; Steinhoff 
et al. 1986).
Neutrophils function at the site of injury 
to initiate the debridement of damaged tissue, 
phagocytose any pathogens, and amplify the 
inflammatory response through production of 
cytokines (Coussens and Werb 2002; Eming 
et al. 2007). A major function of macrophages 
is to continue phagocytosis at sites of tissue 
injury (Freeman et al. 2007). To this end, 
neutrophils and macrophages release highly 
active substances, including reactive oxygen 
species (ROS) and reactive nitrogen species 
that may promote a micro  environment that 
directly damages DNA or interferes with the 
mechanisms of DNA repair (Azad et al. 2008; 
Federico et al. 2007). In the context of Cr(VI) 
exposure, these reactive species may further 
exacerbate DNA damage in surviving and/or 
proliferating epithelial cells and thus promote 
initiating events in Cr(VI) carcinogenesis 
(O’Brien et al. 2003). Macrophages also pro-
duce cytokines and growth factors in order to 
stimulate cell proliferation and angiogenesis 
(reviewed by Eming et al. 2007).
Neutrophils release proteases in response 
to injury, including MMPs, to degrade the 
collagens of the extracellular matrix (Coussens 
and Werb 2002; Eming et al. 2007). Here 
we report a correlation between neutrophil 
presence and pro-MMP9 levels in airways 
after repetitive particulate Cr(VI) exposure. 
MMP9 has been shown to play important 
roles in other lung diseases and is critical in 
neutrophilic inflammation after ventilator-
induced lung injury (Kim et al. 2006). MMPs 
have been shown to promote inflammation 
and fibrosis in asbestos-induced lung injury 
in mice (Tan et al. 2006). It should be noted 
that expression and activation of MMP9 by 
macrophages can be induced indirectly, as well 
as directly, by ROS secreted by inflamma-
tory cells (Svineng et al. 2008). Thus, ROS 
may participate not only in neoplasia but 
also in perpetuating an inflammatory micro-
environment that actively facilitates tumor 
progression in the lung. Taken together, we 
propose that the repeated influx of neutro-
phils followed by the chronic presence of 
macrophages leads to tissue that is repetitively 
injured, thereby promoting a microenviron-
ment that actively facilitates Cr(VI)-induced 
neoplastic progression in the lung. In support 
of this, a recent study in mice also suggests 
that a chronic inflammatory response to weld-
ing fumes may enhance tumorigenesis in the 
lung (Zeidler-Erdely et al. 2008).
Similar to Cr(VI), chronic exposures to 
asbestos, nickel, and beryllium have been asso-
ciated with inflammation and increased lung 
cancer risk (Mossman and Churg 1998; Oller 
2002; Salehi et al. 2009). Although some clear 
differences in these chemicals and the result-
ing lung pathology exist, it is interesting to 
note some similarities among particle-medi-
ated lung inflammation (Mossman and Churg 
1998). For example, exposure to both Cr(VI) 
and asbestos particles induced pneumonitis, 
the recruitment of neutrophils, macrophages, 
and lymphocytes, and the production of 
IL-8 in lung airways (Chapman et al. 2003). 
The detailed mechanisms are not completely 
understood, but a pattern between chronic 
lung inflammation and increased cancer risk is 
clearly emerging in the literature.
A small portion of the lymphoid cells 
recruited to the lung after Cr(VI) exposure 
were positive for the proliferation marker 
Ki-67. Proliferating lymphoid cells have 
been observed in lung tissue under patho-
logic conditions including follicular bron-
chiolitis, lymphoid interstitial pneumonia, 
chronic hyper  sensitivity pneumonitis, asthma, 
and malignant lymphoma (Nicholson et al. 
1995; Suda et al. 1999). We also observed 
binucleated or dividing macrophages, which 
is consistent with the literature on exposure 
of the lung to other carcinogens and is indic-
ative of clastogenic/cytogenetic damage to 
alveolar macrophages (Balansky et al. 1999). 
Further studies are needed to understand the 
mechanism that might be driving the Cr(VI)-
induced proliferation of leukocytes.
We also observed that repetitive Cr(VI) 
exposure resulted in enhanced phosphoryla-
tion of Akt in epithelial cells of both injured 
and proliferative airways. These results are 
consistent with our previous study showing an 
increase in lung epithelial Akt phosphorylation 
at 1 and 24 hr after a single Cr(VI) exposure, 
although the mechanism by which Cr(VI) 
up-regulates Akt phosphorylation is not clear 
at this time. It is possible that the Src family of 
protein tyrosine kinases and/or the regulatory 
subunit of phosphoinositide-3-kinase, p85, is 
activated in vivo, in a similar manner to their 
activation by Cr(VI) in cultured lung cells, 
thus possibly resulting in Akt phosphorylation 
(O’Hara et al. 2003; and data not shown). 
Akt activation has been linked to inflamma-
tion, neutrophil migration, protection against 
oxidant, mechanical-induced lung injury, and 
increased tissue repair (Lai et al. 2007; Li et al. 
2007; Ray et al. 2003). Thus, Cr(VI)-induced 
up-regulation of Akt may promote inflamma-
tion, cell survival, and repair of the airways 
after lung injury. In keeping with this hypoth-
esis, we observed enhanced Ki-67 staining in 
proliferative epithelial cells, which is consistent 
with a role for Akt signaling in promoting 
cell survival in an environment of genotoxic 
Cr(VI)-induced injury and inflammation.
Conclusion
The goal of this study was to gain insight into 
the disease process by which an occupationally 
and possibly environmentally relevant human 
carcinogen induces chronic lung damage. This 
study demonstrates that repetitive exposure to 
particulate Cr(VI) induces chronic inflam-
mation and injury in the lung. Furthermore, 
this Cr(VI)-induced injury and inflammation 
was associated with enhanced survival signal-
ing and epithelial cell proliferation. Taken 
together, we suggest that these early disease 
processes promote a microenvironment that 
may participate in the initiation and promo-
tion of neoplastic cells and contribute over 
time to Cr(VI) carcinogenesis.Beaver et al.
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